Drug Type Autologous CAR-T |
Synonyms MB-CART 2219.1 |
Target |
Action inhibitors |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD22 inhibitors(CD22 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Phase 1 | Germany | 23 Jun 2025 | |
| Burkitt Lymphoma | Phase 1 | Germany | 23 Jun 2025 | |
| Chronic lymphocytic leukaemia refractory | Phase 1 | Germany | 23 Jun 2025 | |
| Diffuse Large B-Cell Lymphoma | Phase 1 | Germany | 23 Jun 2025 | |
| Extramedullary Disease in Multiple Myeloma | Phase 1 | Germany | 23 Jun 2025 | |
| Follicular Lymphoma | Phase 1 | Germany | 23 Jun 2025 | |
| Large B-cell lymphoma | Phase 1 | Germany | 23 Jun 2025 | |
| Mantle-Cell Lymphoma | Phase 1 | Germany | 23 Jun 2025 | |
| Marginal Zone B-Cell Lymphoma | Phase 1 | Germany | 23 Jun 2025 | |
| Philadelphia positive acute lymphocytic leukaemia | Phase 1 | Germany | 23 Jun 2025 |
Phase 1/2 | 14 | andzvjpgfo(uhrzwetmeu) = nyfwlkuepj yfjvgqfvrd (knxiyyuirx, 15.0) View more | Positive | 06 Dec 2025 |





